Luteolin prevents uric acid-induced pancreatic β-cell dysfunction

Area of Science:

• Biochemistry
• Cell Biology
• Endocrinology

Background:

• Elevated uric acid (hyperuricemia) can directly injure pancreatic beta cells, impairing their function.
• Beta-cell dysfunction is a key factor in diabetes development, particularly in conditions associated with hyperuricemia.

Purpose of the Study:

• To investigate the protective effects of luteolin, a natural antioxidant, against uric acid-induced pancreatic beta-cell dysfunction.
• To elucidate the molecular mechanisms underlying luteolin's protective actions.

Main Methods:

• Assessed nitric oxide (NO) production using the Griess method in uric acid-stimulated Min6 cells.
• Measured nuclear factor-kappa B (NF-κB) transcriptional activity via reporter assays.
• Analyzed MafA and inducible nitric oxide synthase (iNOS) expression using Western blotting.
• Evaluated the impact of luteolin on glucose-stimulated insulin secretion (GSIS) in Min6 cells and mouse pancreatic islets.

Main Results:

• Luteolin significantly inhibited uric acid-induced NO production, correlating with reduced iNOS expression.
• Luteolin decreased NF-κB activity, which was linked to the inhibition of uric acid-induced iNOS expression.
• Luteolin increased MafA expression in uric acid-treated cells, an effect reversed by iNOS overexpression.
• Luteolin prevented the inhibition of GSIS caused by uric acid in both cell lines and primary islets.

Conclusions:

• Luteolin demonstrates significant protective effects against uric acid-induced pancreatic beta-cell dysfunction.
• The protective mechanisms involve the inhibition of NO production via reduced iNOS expression and NF-κB activity, and the preservation of MafA expression.
• Luteolin may offer therapeutic benefits for managing diabetes linked to hyperuricemia.